Insulin Lispro
Approved · EMAAlso known as Admelog, HumaLOG, Humalog Mix, Lispro PRC+6 more
Admelog, HumaLOG, Humalog Mix, Lispro PRC, Lispro insulin, Lyumjev, Insulina lispro, INSULIN,LISPRO,HUMAN/rDNA, Insulin lispro protamine recombinant, Insulin lispro recombinant.
Recent clinical, regulatory, research and industry developments relating to this drug.
Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?
Approval: Lyumjev (previously Liumjev) (EMA)
Approval: Insulin lispro Sanofi (EMA)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Bysumlog is also indicated for the initial… Show full indicationShow less
For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Bysumlog is also indicated for the initial stabilisation of diabetes mellitus.
Indication: Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. Treatment of diabetes mellitus in adults.
Evidence ↗Indication: For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Insulin lispro Sanofi is also indicated for… Show full indicationShow less
For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Insulin lispro Sanofi is also indicated for the initial stabilisation of diabetes mellitus.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Diabetes technology & therapeutics5
- Muchmore DB3
- Vaughn DE3
- Hompesch M2
- Morrow L2
- Allen JM1
- Bailey TS1
- Bally L1
- Bilinsky IP1
- Profil Institute for Clinical Research2
- 1 Institut für Klinische Forschung und Entwicklung (IKFE) Berlin GmbH1
- 2 AMCR Institute1
- Bern University Hospital1
- Cambridge University Hospitals NHS Foundation Trust1
- Endocrinology and Metabolism Centre1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Insulin Lispro, with an overlapping disease area.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.